Abstract
Introduction: Advance planning of the design and analysis of vaccine trials conducted during infectious disease outbreaks increases our ability to rapidly define the efficacy and potential impact of a vaccine and inform public health response. Vaccine efficacy against infectiousness (VEI) is an important measure for understanding the full impact of a vaccine, yet it is currently not identifiable in many vaccine trial designs because it requires knowledge of the vaccination status of infectors. Recent advances in pathogen genomics have improved our ability to accurately reconstruct transmission networks. We aim to assess if augmenting classical randomized controlled trial designs with pathogen sequence and contact tracing data can permit these trials to estimate VEI. Methods: We develop a transmission model with a vaccine trial in an outbreak setting, incorporate pathogen sequence evolution data and sampling as well as contact tracing data, and assign probabilities to likely infectors. We then propose and evaluate the performance of an estimator of VEI. Results: We find that under perfect knowledge of infector-infectee pairs, we are able to accurately estimate VEI. Use of sequence data results in imperfect reconstruction of the transmission networks, biasing estimates of VEI towards the null, with approaches using deep sequence data performing better than approaches using consensus sequence data. Inclusion of contact tracing data reduces the bias. Conclusion: Pathogen genomics enhance identifiability of VEI from individually randomized controlled trials, but imperfect transmission network reconstruction biases the estimates towards the null and limits our ability to detect VEI. Given the consistent direction of the bias, estimates obtained from trials using these methods will provide lower bounds on the true VEI. A combination of sequence and epidemiologic data results in the most accurate estimates, underscoring the importance of contact tracing in reconstructing transmission networks.
Competing Interest Statement
ML discloses honoraria/consulting from Merck, Affinivax, Sanofi-Pasteur, and Antigen Discovery; research funding (institutional) from Pfizer, and an unpaid scientific advice to Janssen, Astra-Zeneca, and Covaxx (United Biomedical).
Funding Statement
This research is funded by the Department of Health and Social Care using UK Aid funding and is managed by the NIHR. RW was supported by funding from R01 AI136947 from the National Institute of Allergy and Infectious Diseases. SVL was supported by NIHGMS R01GM122876 and T32GM074905. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health and SocialCare or the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
